The Committee on Safety of Medicines recommended that blood products should not be sourced from UK plasma, due to the theoretical risk that nvCJD could be transmitted by blood products which could not be discounted. Read more about The Committee on Safety of Medicines recommended that blood products should not be sourced from UK plasma, due to the theoretical risk that nvCJD could be transmitted by blood products which could not be discounted.
A study showed that there was a prevalence of infection of about 1 in 4000 people, albeit from a limited sized study. Read more about A study showed that there was a prevalence of infection of about 1 in 4000 people, albeit from a limited sized study.
The Lothian Research Ethics Committee was where the NCJDSU had to apply to for ethical clearance for proposed retrospective study to examine the possible link between CJD and blood transfusion, known at the TMER study (Transfusion Medicine Epidemiology Review) on the condition that anyone traced as a result of the study, would not be told of their exposure. Read more about The Lothian Research Ethics Committee was where the NCJDSU had to apply to for ethical clearance for proposed retrospective study to examine the possible link between CJD and blood transfusion, known at the TMER study (Transfusion Medicine Epidemiology Review) on the condition that anyone traced as a result of the study, would not be told of their exposure.
In a paper published by the Department of Health into research on a link between new variant CJD and BSE, the publication of the latest scientific advice concluded that the evidence that had accumulated since March 1996 was consistent with the hypothesis that nvCJD was caused by exposure to the BSE agent. Read more about In a paper published by the Department of Health into research on a link between new variant CJD and BSE, the publication of the latest scientific advice concluded that the evidence that had accumulated since March 1996 was consistent with the hypothesis that nvCJD was caused by exposure to the BSE agent.
It was only in the financial year 2004/5 that all patients with Haemophilia A in the UK were treated with recombinant Factor 8. Read more about It was only in the financial year 2004/5 that all patients with Haemophilia A in the UK were treated with recombinant Factor 8.
In the CJDIP document on the management of possible exposure to CJD through medical procedures, the section on managing blood incidents had been greyed out as it had not yet been finalised. Read more about In the CJDIP document on the management of possible exposure to CJD through medical procedures, the section on managing blood incidents had been greyed out as it had not yet been finalised.
In September 2004, patients with bleeding disorders were informed about vCJD by their haemophilia centre and given an opportunity to discuss the implications and given the option to find out if they had received an implicated batch if they wished. Read more about In September 2004, patients with bleeding disorders were informed about vCJD by their haemophilia centre and given an opportunity to discuss the implications and given the option to find out if they had received an implicated batch if they wished.
An interim trust was set up in April 2001 and interim payments of £25,000 would be made to families of those who had been diagnosed with vCJD. Read more about An interim trust was set up in April 2001 and interim payments of £25,000 would be made to families of those who had been diagnosed with vCJD.
The Scottish Office made sufficient funding available for recombinant Factor 8 for young or new patients, but in due course this was to extend to all patients. Read more about The Scottish Office made sufficient funding available for recombinant Factor 8 for young or new patients, but in due course this was to extend to all patients.
In a background note for the House of Commons, it was stated that the Secretary of State had agreed to subsidise the additional cost of moving from plasma-derived Factor 8 to the commercial synthetic product, which could take a number of years. Read more about In a background note for the House of Commons, it was stated that the Secretary of State had agreed to subsidise the additional cost of moving from plasma-derived Factor 8 to the commercial synthetic product, which could take a number of years.